As chemical raw materials, raw materials are the basic raw materials of drug production, which directly affects the quality and production capacity of drugs. With the rapid development of the pharmaceutical market, the demand for apis continues to increase. Data show that the global API market size has reached 165.7 billion US dollars in 2018, and it is expected that the market size will reach 236.7 billion US dollars by 2024, with a compound annual growth rate of 6.12%.
China is the world’s API production and export power, in recent years, China has introduced various industrial policies to guide the API industry to high-quality development. For example, the “Guiding Opinions on Promoting the Green Development of the API Industry” clearly states that by 2025, the industrial structure will be more reasonable, the proportion of apis produced by green processes will be further increased, and the market share of high-end specialty apis will be significantly increased; The industrial layout is more optimized, the production of apis is basically realized in the park, and a number of centralized production bases for apis are built. The technical level has been effectively improved, breaking through more than 20 green key common technologies, and basically realizing the substitution of green production technology in the industry; Continuous improvement of green standards, the establishment of API green factory, green park, green management standard evaluation system, giving play to the leading role of competitive enterprises in green development; The level of cleaner production has been significantly improved, and energy consumption per unit of industrial added value, carbon dioxide emissions, water consumption, and the emission intensity of major pollutants such as sulfur dioxide, nitrogen oxides, and volatile organic compounds have gradually decreased.
It is reported that in addition to the policies at the national level, 31 provinces and cities in China have also issued local policy planning for the API industry, involving the expected target of output value and industrial supporting development support.
National policies to support API enterprises, with volume procurement to promote sales growth, consistency evaluation to enhance the bargaining power of API enterprises…… Driven by a series of policies, China’s API industry has maintained steady growth. The raw materials produced in China not only occupy an important position in the country, but also have a pivotal position in the global pharmaceutical industry chain. It is expected that by 2028, the market size of enterprises above designated size in China’s chemical raw material industry will exceed 680 billion yuan, with an annual compound growth rate of 4.2%.
About Zhichao Medicine
Zhichao Chemical, more than 10 years of pharmaceutical intermediates manufacturers, headquartered in Changzhou Hang Seng Science and Technology Industrial Park. API or pharmaceutical intermediates, plant extracts process research and development, production, optimization, custom synthesis and technology transfer, compounds from laboratory scale to commercial scaleup production, can meet the individual needs of different customer groups. We attach importance to R&D technology investment, establish long-term strategic cooperative relations with domestic and foreign academies of sciences, and set up branches in India. In strict accordance with the international GMP standard management, the products are exported to Europe, America, India, Southeast Asia, the Middle East and South America
